<DOC>
	<DOCNO>NCT01093911</DOCNO>
	<brief_summary>To evaluate safety , tolerability , pharmacokinetics immunogenicity CDP7657</brief_summary>
	<brief_title>Safety Study CDP7657 Healthy Volunteers Patients With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<criteria>Healthy Volunteers subject SLE Severe neuropsychiatric severe renal SLE History chronic , recurrent , recent severe infection Significant hematologic abnormality History cancer , heart failure , renal disease , liver disease serious illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
</DOC>